The complexity of demands on Market Access teams has increased in recent years, between introducing innovative therapies targeting smaller populations and higher bars from Payers and PBMs. Now, drug manufacturers are bucking up. According to the IQVIA Institute, the prescription abandonment rate has reached 27 percent, or $76 billion annually, in specialty drugs alone. This squandered revenue has led manufacturers to increase their focus on the complex, nuanced patient journey. As a
Read More
Pharma
When Innovation Isn’t Enough: Pharma’s Next Frontier
I met Mark Cuban once. Our conversation didn’t last very long. It was at a medical conference a few years ago. Cuban felt like a great guy to approach with an idea for a healthcare startup. We were both investors in an automation software startup called Zoba, and I of course knew him from his role on the popular entrepreneurial reality TV series Shark Tank. A few seconds into our conversation, Cuban paused. “Healthcare is hard,” he sighed. That was his way of politely telling me: for that
Read More
Analysis: RSNA 2022: Predictions vs Reality
Much has already been written about attendance at RSNA, but from a first-hand perspective, RSNA 2022 could be regarded as a step back toward “normal”. Amongst mostly bustling halls, vendors reported very positive feedback on the volume and quality of customer meetings, with one prominent global imaging vendor citing “We’re signing deals here at the show again – things are looking up”. Against this positive backdrop, however, the stark challenges facing radiology in a post-COVID world were
Read More
AI/ML Used for Clinical Trial-Site Identification Simultaneously Improves Enrollment Rates and Diversity
Ethnic and racial minorities are commonly underrepresented in clinical trials. This problem is so severe that in April, the U.S. Food and Drug Administration (FDA) expanded upon existing guidance to further emphasize recommendations to sponsors developing treatments to increase enrollment from underrepresented populations in the U.S., including African-American, Hispanic, Asian and other persons of color, in clinical trials. In the updated guidance, the FDA provided details on what sponsors
Read More
Protecting AI’s Boundless Potential in Healthcare
Artificial intelligence can do amazing things for patients, providers and the healthcare business — but only if the right cyber safeguards are in place. For more than a decade, a cybercrime syndicate known as Evil Corp has tormented organizations around the world with malware and ransomware attacks. And now, it seems, the group has designs on healthcare companies. “Evil Corp should be considered a significant threat to the U.S. health sector,” the Health Sector Cybersecurity
Read More
Specialty Pharma’s Next Big Opportunity: It’s Time for Patient Access to Adopt an Open Protocol
In January 2020, the financial conglomerate Visa announced it was acquiring a relatively unknown startup, Plaid, for $5.3 billion. Corporate acquisitions like these are not uncommon, but someone at the United States Department of Justice took notice of this announcement. Visa had established a stranglehold on financial transactions. The Justice Department moved to stop the acquisition on grounds that Plaid posed “a threat to this monopoly: it has been developing an innovative
Read More
Site Enablement Platforms Can Accelerate Clinical Trials by 6 Weeks and Reduce Costs by Over $1M
What You Should Know: - Florence HealthcareTM, a clinical research technology company headquartered in Atlanta, Georgia, recently announced the completion of a year-long third-party study on the impact of Site Enablement PlatformsTM on clinical research timelines and costs. - The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor
Read More
The $2.8M Medicine: How Data Can Help Insurers Pay for Life-Changing Therapies Without Breaking The Bank
Advanced medical research has brought us to the point where many serious conditions can potentially be treated and even cured - with people who have essentially faced a lifetime of being incapacitated finally able to conduct normal lives. Many of these treatments are drug-based gene therapies–- but they come with an extremely high price tag. The latest example–and most expensive medication to date– is bluebird bio’s recently-approved $2.8 million gene therapy to treat a rare blood
Read More
ConcertAI CEO Talks COVID-19 & The De-Risking of Technology to Keep Trials Moving
Nothing like it had ever happened before – a global slowdown in new study starts and a massive decrease in trial accruals for open studies. The turn of events was a shock for sponsors and providers. Sudden disruptions on that scale rarely hit multiple players in an ecosystem at the same time. But that’s exactly what happened at the intersection of clinical care and clinical development during the pandemic. Researchers and clinicians were forced to change how they operated trials, and
Read More
Drug Price Transparency: Planning for Change
Currently, some 22 states have enacted prescription drug transparency laws that require entities across the drug supply chain to report pricing information to state officials. Designed to shed light on the true cost of drugs and to ensure that consumers and insurers aren’t being gouged, drug pricing transparency laws seek to level the playing field by delivering greater visibility into drug costs. And given the fact that prescription drug prices continue to increase, the topic of drug price
Read More
